Product Name
SLC6A19, Blocking Peptide
Full Product Name
SLC6A19 Blocking Peptide (C-Term)
Product Synonym Names
Sodium-dependent neutral amino acid transporter B(0)AT1; Solute carrier family 6 member 19; System B(0) neutral amino acid transporter AT1; SLC6A19; B0AT1
Product Gene Name
SLC6A19 blocking peptide
[Similar Products]
Product Synonym Gene Name
B0AT1[Similar Products]
SLC6A19 peptide (MBS9230649) is used for blocking the activity of SLC6A19 antibody (MBS9217212)
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q695T7
Specificity
The synthetic peptide sequence is selected from aa 564-575 of HUMAN SLC6A19
Form/Format
Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.
Cellular Location
Membrane; Multi-pass membrane protein
Tissue Location
Robust expression in kidney and small intestine, with minimal expression in pancreas. Also expressed in stomach, liver, duodenum, ileocecum, colon and prostate. Not detected in testis, whole brain, cerebellum, fetal liver, spleen, skeletal muscle, uterus, heart or lung
Preparation and Storage
Maintain refrigerated at 2-8 degree C for up to 6 months. For long term storage store at -20 degree C.
Other Notes
Small volumes of SLC6A19 blocking peptide vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
SLC6A19 blocking peptide
Transporter that mediates epithelial resorption of neutral amino acids across the apical membrane of epithelial cells in the kidney and intestine. It appears that leucine is the preferred substrate, but all large neutral non-aromatic L-amino acids bind to this transporter. Uptake of leucine is sodium- dependent. In contrast to other members of the neurotransmitter transporter family, does not appear to be chloride-dependent (By similarity).
NCBI/Uniprot data below describe general gene information for SLC6A19. It may not necessarily be applicable to this product.
NCBI Accession #
Q695T7.1
[Other Products]
UniProt Primary Accession #
Q695T7
[Other Products]
UniProt Secondary Accession #
A8K446[Other Products]
UniProt Related Accession #
Q695T7[Other Products]
Molecular Weight
71,110 Da
NCBI Official Full Name
Sodium-dependent neutral amino acid transporter B(0)AT1
NCBI Official Synonym Full Names
solute carrier family 6 member 19
NCBI Official Symbol
SLC6A19??[Similar Products]
NCBI Official Synonym Symbols
HND; B0AT1
??[Similar Products]
NCBI Protein Information
sodium-dependent neutral amino acid transporter B(0)AT1
UniProt Protein Name
Sodium-dependent neutral amino acid transporter B(0)AT1
UniProt Synonym Protein Names
Solute carrier family 6 member 19; System B(0) neutral amino acid transporter AT1
Protein Family
Sodium-dependent neutral amino acid transporter
UniProt Gene Name
SLC6A19??[Similar Products]
UniProt Synonym Gene Names
B0AT1??[Similar Products]
UniProt Entry Name
S6A19_HUMAN
NCBI Summary for SLC6A19
This gene encodes a system B(0) transmembrane protein that actively transports most neutral amino acids across the apical membrane of epithelial cells. Mutations in this gene result in Hartnup disorder. [provided by RefSeq, Jul 2008]
UniProt Comments for SLC6A19
SLC6A19: Transporter that mediates epithelial resorption of neutral amino acids across the apical membrane of epithelial cells in the kidney and intestine. It appears that leucine is the preferred substrate, but all large neutral non-aromatic L-amino acids bind to this transporter. Uptake of leucine is sodium- dependent. In contrast to other members of the neurotransmitter transporter family, does not appear to be chloride-dependent. Defects in SLC6A19 are a cause of Hartnup disorder (HND). HND is an autosomal recessive abnormality of renal and gastrointestinal neutral amino acid transport noted for its clinical variability. First described in 1956, HND is characterized by increases in the urinary and intestinal excretion of neutral amino acids. Individuals with typical Hartnup aminoaciduria may be asymptomatic, some develop a photosensitive pellagra-like rash, attacks of cerebellar ataxia and other neurological or psychiatric features. Although the definition of HND was originally based on clinical and biochemical abnormalities, its marked clinical heterogeneity has led to it being known as a disorder with a consistent pathognomonic neutral hyperaminoaciduria. Defects in SLC6A19 may be a cause of hyperglycinuria (HG). It is a condition characterized by excess of glycine in the urine. In some cases it is associated with renal colic and renal oxalate stones. SLC6A19 deficiency combined with haploinsufficiency of SLC6A20 or partially inactivating mutations in SLC36A2, can be responsible for hyperglycinuria. Defects in SLC6A19 may be a cause of iminoglycinuria (IG). It is a disorder of renal tubular reabsorption of glycine and imino acids (proline and hydroxyproline), marked by excessive levels of all three substances in the urine. SLC6A19 deficiency combined with haploinsufficiency of SLC6A20 or partially inactivating mutations in SLC36A2, can be responsible for iminoglycinuria. Additional polymorphisms and mutations in SLC6A18 can contribute to the IG phenotype in some families. Belongs to the sodium:neurotransmitter symporter (SNF) (TC 2.A.22) family. SLC6A19 subfamily.
Protein type: Transporter; Membrane protein, integral; Transporter, SLC family; Membrane protein, multi-pass
Chromosomal Location of Human Ortholog: 5p15.33
Cellular Component: integral to plasma membrane; plasma membrane
Molecular Function: amino acid transmembrane transporter activity; neutral amino acid transmembrane transporter activity
Biological Process: amino acid transport
Disease: Hartnup Disorder; Hyperglycinuria; Iminoglycinuria
Research Articles on SLC6A19
1. SIT1, B(0)AT1 and ACE2 were co-localized in the brush-border membrane of small intestine enterocytes.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.